Samsung Biologics Implements QbD for Biopharmaceutical Product Lifecycle Management
04/21/25, 9:40 AM
Location
south koreaIndustry
biotechnology
manufacturing
Type
contract
Youngsun Kim and Busol Park from Samsung Biologics discuss the benefits of using a Quality-by-design approach for biologics manufacturing. This approach facilitates the production of safe and consistent drugs, addressing the need for rigorous manufacturing standards throughout the lifecycle of biopharmaceutical products.
Company Info
Location
south korea
Additional Info
Samsung Biologics is a fully integrated contract development and manufacturing organization (CDMO) that offers comprehensive services from cell line development to final aseptic fill/finish. The company operates state-of-the-art, CGMP compliant facilities and has increased its biomanufacturing capacity to meet growing demand. With a commitment to innovative technologies and customized solutions, Samsung Biologics supports its clients' evolving needs in the biopharmaceutical sector. The company also has a presence in the U.S. and Europe to better collaborate with international clients.